. Author manuscript; available in PMC: 2016 Feb 9.

Published in final edited form as: J Clin Lipidol. 2014 Oct 13;9(1):93–102. doi: 10.1016/j.jacl.2014.09.013

Table 3.

Percent change from baseline to week 8 in whole plasma lipid concentrations between treatment groups

	Difference in LS mean percent change from baseline (95% CI)^*
Parameter (mg/dL)	Placebo vs anacetrapib alone	Placebo vs atorvastatin alone	Atorvastatin alone vs anacetrapib + atorvastatin
TC	2.0 (−2.4, 6.4)	−31.0 (−36.1, −26.0)^†	9.3 (5.1, 13.5)^†,‡
LDL-C	−43.3 (−49.9, −36.7)^†,‡	−45.7 (−53.3, −38.0)^†	−24.5 (−30.8, −18.1)^†,‡
HDL-C	134.4 (120.9, 147.9)^†,‡	1.28 (−14.4, 16.9)	121.4 (108.4, 134.4)^†,‡
TG^§	26.4 (−16.8, 3.5)	−21.2 (−33.0, −10.5)^†	−5.12 (−13.2, 1.5)
Non–HDL-C	−36.0 (−41.6, −30.4)^†,‡	−40.7 (−47.2, −34.2)^†	−20.7 (−26.2, −15.3)^†,‡
Apo B	−32.1 (−37.0, −27.2)^†,‡	−36.3 (−41.9, −30.6)^†	−14.4 (−19.1, −9.7)^†,‡
Apo AI	41.3 (35.4, 47.1)^†,‡	−2.9 (−9.7, 4.0)	39.1 (33.5, 44.8)^†,‡
Lp(a)^§	−42.9 (−57.6, −31.3)^†,‡	0.00 (−7.6, 13.0)	−38.08 (−50.0, −27.0)^†,‡

apoAI, apolipoprotein AI; apoB, apolipoprotein B; atorvastatin, atorvastatin 20 mg; CI, confidence interval; HDL, high-density lipoprotein; IQR, interquartile range; LDL, low-density lipoprotein; Lp(a), lipoprotein(a); TC, total cholesterol; TG, triglyceride.

LDL-C estimated using Friedewald equation.

Anacetrapib, combined anacetrapib 150- and 300-mg treatment groups.

Least squares mean and 95% CI from analysis of covariance model with treatment as a factor and baseline lipid level as a covariate.

^†

Significant between-group difference with 2-stage false discovery rate approach, which ensures the overall false discovery rate to be less than 5%.

^‡

Significant dose-response including placebo and all anacetrapib doses (ie, 10 mg, 40 mg, 150 mg/300 mg).

^§

Hodges-Lehman estimate of median and distribution-free CI presented for change from baseline results; median ± IQR presented at baseline and week 8.